GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » 5-Year Yield-on-Cost %

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 30, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics 5-Year Yield-on-Cost %?

Brainstorm Cell Therapeutics's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



BCLI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.825
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost % falls into.



Brainstorm Cell Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Brainstorm Cell Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Brainstorm Cell Therapeutics  (NAS:BCLI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Brainstorm Cell Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Executives
Stacy Lindborg officer: EVP, Head Global Clin Research C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor director BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor officer: Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits officer: Chief Executive Officer 110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun officer: EVP and COO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd. other: Member of 10% owner group MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi director 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel director 188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya officer: Chief Commercial Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah officer: EVP, CFO and Treasurer C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel director 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Headlines

From GuruFocus